176 related articles for article (PubMed ID: 26286116)
1. Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.
Teramachi J; Silbermann R; Yang P; Zhao W; Mohammad KS; Guo J; Anderson JL; Zhou D; Feng R; Myint KZ; Maertz N; Beumer JH; Eiseman JL; Windle JJ; Xie XQ; Roodman GD; Kurihara N
Leukemia; 2016 Feb; 30(2):390-8. PubMed ID: 26286116
[TBL] [Abstract][Full Text] [Related]
2. XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the
Adamik J; Silbermann R; Marino S; Sun Q; Anderson JL; Zhou D; Xie XQ; Roodman GD; Galson DL
Front Endocrinol (Lausanne); 2018; 9():344. PubMed ID: 30008697
[TBL] [Abstract][Full Text] [Related]
3. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.
Hiruma Y; Honjo T; Jelinek DF; Windle JJ; Shin J; Roodman GD; Kurihara N
Blood; 2009 May; 113(20):4894-902. PubMed ID: 19282458
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.
Marino S; Petrusca DN; Bishop RT; Anderson JL; Sabol HM; Ashby C; Layer JH; Cesarano A; Davé UP; Perna F; Delgado-Calle J; Chirgwin JM; Roodman GD
Haematologica; 2024 May; 109(5):1501-1513. PubMed ID: 37981834
[TBL] [Abstract][Full Text] [Related]
5. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
6. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
[TBL] [Abstract][Full Text] [Related]
7. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
8. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
9. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease.
Kurihara N; Hiruma Y; Zhou H; Subler MA; Dempster DW; Singer FR; Reddy SV; Gruber HE; Windle JJ; Roodman GD
J Clin Invest; 2007 Jan; 117(1):133-42. PubMed ID: 17187080
[TBL] [Abstract][Full Text] [Related]
10. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.
Rea SL; Walsh JP; Ward L; Yip K; Ward BK; Kent GN; Steer JH; Xu J; Ratajczak T
J Bone Miner Res; 2006 Jul; 21(7):1136-45. PubMed ID: 16813535
[TBL] [Abstract][Full Text] [Related]
11. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
13. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
14. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Mitsiades C; Chauhan D; Okawa Y; Munshi NC; Richardson PG; Anderson KC
Leukemia; 2008 Oct; 22(10):1925-32. PubMed ID: 18596740
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
Yaccoby S; Wezeman MJ; Zangari M; Walker R; Cottler-Fox M; Gaddy D; Ling W; Saha R; Barlogie B; Tricot G; Epstein J
Haematologica; 2006 Feb; 91(2):192-9. PubMed ID: 16461303
[TBL] [Abstract][Full Text] [Related]
17. D-amino acid inhibits biofilm but not new bone formation in an ovine model.
Harmata AJ; Ma Y; Sanchez CJ; Zienkiewicz KJ; Elefteriou F; Wenke JC; Guelcher SA
Clin Orthop Relat Res; 2015 Dec; 473(12):3951-61. PubMed ID: 26201421
[TBL] [Abstract][Full Text] [Related]
18. Dual effect of WIN-34B on osteogenesis and osteoclastogenesis in cytokine-induced mesenchymal stem cells and bone marrow cells.
Seo BK; Ryu HK; Park YC; Huh JE; Baek YH
J Ethnopharmacol; 2016 Dec; 193():227-236. PubMed ID: 27401292
[TBL] [Abstract][Full Text] [Related]
19. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.
Ehrlich LA; Chung HY; Ghobrial I; Choi SJ; Morandi F; Colla S; Rizzoli V; Roodman GD; Giuliani N
Blood; 2005 Aug; 106(4):1407-14. PubMed ID: 15878977
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.
Lu A; Pallero MA; Lei W; Hong H; Yang Y; Suto MJ; Murphy-Ullrich JE
Am J Pathol; 2016 Mar; 186(3):678-90. PubMed ID: 26801735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
